Data protection Impressum

Healthcare

A new study conducted at Bern’s University Hospital shows that VisionOne, the virtual reality eye-testing platform developed by Vaud-based PeriVision, delivers clinical performance comparable to the stationary perimeter considered the gold standard, including in advanced glaucoma.

PeriVision’s VR eye test matches the gold standard across glaucoma severity

17 August 2026

Oculis, the Lausanne-based biopharmaceutical company focused on ophthalmology and neuro-ophthalmology, will acquire all worldwide development and commercial rights to Privosegtor from Accure, terminating its existing license agreement.

Oculis acquires worldwide rights to its Privosegtor candidate

17 August 2026

Researchers at EPFL, with colleagues from the University of Geneva, Geneva University Hospitals and Zurich, have developed VirTues, an AI foundation model for tissue biology that analyzes tumor tissue across many cancer types, with results published in Nature.

EPFL’s VirTues AI model maps tumor tissue across cancer types

17 August 2026

Top Stories Western Switzerland

Top Stories from Western Switzerland (July 2026)

3 August 2026

AB2 Bio has received a USD 30 million payment after Japanese pharmaceutical company Nippon Shinyaku exercised its option to commercialize Tadekinig alfa in the United States, with up to USD 600 million in further milestone and royalty payments.

AB2 Bio receives USD 30 million as Nippon Shinyaku takes up US rights

3 August 2026

Hilo closes a USD 19 million Series B extension to fuel its US expansion

3 August 2026

MoleSense and Impli, both based at the Biopôle life sciences campus, have been selected by Germany's Federal Agency for Breakthrough Innovation to develop biosensors capable of continuously measuring at least four hormones over seven days.

MoleSense and Impli selected for the SPRIND Challenge on continuous hormone monitoring

3 August 2026

HeroSupport, a Geneva-based medtech company, has announced that NYU Grossman School of Medicine is the first clinical site in the United States to participate in its SHIELD study evaluating the VENUS SHELL breast immobilization device.

HeroSupport opens its first US clinical site for the SHIELD study

3 August 2026

Pilatus Biosciences, a Biopôle-based biotech whose lead therapy originated in research conducted in Lausanne, has established a subsidiary in Hong Kong and received regulatory approval to begin a clinical trial of PLT012 in patients with advanced solid tumors.

Pilatus Biosciences takes its Lausanne-born immunotherapy to Hong Kong

3 August 2026

The .NeuroRestore center in Lausanne, led by Jocelyne Bloch and Grégoire Courtine, has been honored with the 2026 Grand Prix scientifique of the NRJ Foundation - Institut de France for its brain-spine interface that restores movement to paralyzed patients.

.NeuroRestore wins part of France’s 2026 NRJ Foundation science grand prix

13 July 2026

1 2 3 4 5 6 … 24